Clearside Biomedical, Inc.CLSDNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank92
5Y CAGR+71.4%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
+71.4%/yr
Long-term compound
Percentile
P92
Near historical high
vs 5Y Ago
14.8x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 85.16% |
| Q2 2025 | -64.51% |
| Q1 2025 | 5.16% |
| Q4 2024 | 2.81% |
| Q3 2024 | -10.32% |
| Q2 2024 | -17.61% |
| Q1 2024 | -11.22% |
| Q4 2023 | 22.57% |
| Q3 2023 | 3.76% |
| Q2 2023 | 11.17% |
| Q1 2023 | -11.07% |
| Q4 2022 | 7.94% |
| Q3 2022 | -14.00% |
| Q2 2022 | 18.87% |
| Q1 2022 | 19.53% |
| Q4 2021 | -26.27% |
| Q3 2021 | 26.77% |
| Q2 2021 | -26.05% |
| Q1 2021 | 22.76% |
| Q4 2020 | 28.14% |
| Q3 2020 | 5.76% |
| Q2 2020 | -13.41% |
| Q1 2020 | 192.03% |
| Q4 2019 | -52.16% |
| Q3 2019 | 314.59% |
| Q2 2019 | -94.00% |
| Q1 2019 | -37.28% |
| Q4 2018 | -12.93% |
| Q3 2018 | 15.80% |
| Q2 2018 | 29.63% |
| Q1 2018 | -3.99% |
| Q4 2017 | -13.18% |
| Q3 2017 | 39.83% |
| Q2 2017 | 51.23% |
| Q1 2017 | 8.88% |
| Q4 2016 | 89.33% |
| Q3 2016 | -12.60% |
| Q2 2016 | -8.19% |
| Q1 2016 | 20.83% |
| Q4 2015 | 64.49% |